| |
TOP
VITAMIN D RESEARCH OF 2014
by William B. Grant, PhD
(OMNS Feb 3, 2015)
Higher vitamin D blood levels may reduce the risk of many
types of disease including autoimmune diseases, cancers,
cardiovascular disease, dementia, diabetes mellitus and
falls and fractures.
Research into the
health effects associated with vitamin D continued to
be strong in 2014. The number of publications with vitamin
D in the title or abstract listed at pubmed.gov increased
from 3,119 in 2011 to 3,919 in 2014. Seven vitamin D researchers
(listed after this report) worked together to pick the
20 papers in 2014 that made the most contribution to understanding
the health effects of vitamin D in 2014.
Papers are not in
priority order, but instead grouped by type of study.
For the purpose of this article "vitamin D"
in the blood is a measurement of 25-hydroxyvitamin D or
25(OH)D.
Do randomized controlled trials work for vitamin D?
No one refutes the
fact that vitamin D is beneficial to the skeletal system.
There are many studies (randomized controlled trials [RCT]
and also epidemiological) that support this hypothesis.
What is at odds is whether or not vitamin D is beneficial
to the non-skeletal system. There are many observational
(epidemiological, or association) studies that show vitamin
D is beneficial, and many RCTs that show it isn't. Does
that mean that vitamin D does not aid in disease prevention?
Or does it mean that the RCT model does not work for nutrients?
RANDOMIZED CONTROL
TRIALS IN 2014
Vitamin D3 supplementation in patients with chronic obstructive
pulmonary disease [Martineau, 2014]
A vitamin D trial in the UK in which patients with chronic
obstructive pulmonary disease (COPD) were given 120,000
IU vitamin D3 every two months for a year found that vitamin
D3 supplementation was protective against moderate or
severe exacerbation in those with baseline 25(OH)D concentrations
< 50 nmol/L (20 ng/mL) but not for those with concentrations
> 50 nmol/L. Vitamin D3 supplementation had no effect
on upper respiratory infections. This is consistent with
previous RCTs that used high doses at infrequent intervals,
every 2 months in this case; however other trials
that used an adequate dose given daily have shown reduction
in upper respiratory tract infections.
VITAMIN D PROMOTES
VASCULAR REGENERATION [WONG, 2014]
This study demonstrated that vitamin D improved cardiovascular
disease. The German team investigated this effect several
ways. They showed that supplementation with 4000 IU/day
of vitamin D3 increased the number of circulating angiogenic
myeloid cells, which promote growth and vascular regeneration
necessary for a healthy cardiovascular system. A similar
result was found in a mouse model, which also demonstrated
restoration of impaired angiogenesis (new vessel formation)
function. They also examined the mechanisms by which vitamin
D acted.
VITAMIN D AND DEPRESSION:
A SYSTEMATIC REVIEW AND META-ANALYSIS COMPARING STUDIES
WITH AND WITHOUT BIOLOGICAL FLAWS. [SPEDDING, 2014]
This paper reported on a statistical average of many studies
of vitamin D RCTs without methodological flaws and found
that vitamin D supplementation resulted in a statistically
significant improvement in clinical depression. However,
the same analysis of vitamin D RCTs with methodological
flaws found a statistically significant worsening of depression.
The major flaws identified included not increasing 25(OH)D
concentrations and not measuring baseline or final 25(OH)D
concentrations. Vitamin D supplementation of > 800
IU/d was somewhat favorable in the management of depression.
EFFECT OF VITAMIN
D SUPPLEMENTATION ON ANTIBIOTIC USE: A RANDOMIZED CONTROLLED
TRIAL. [TRAN, 2014]
A post hoc (conducted after the study was completed) analysis
of a vitamin D RCT involving 644 Australian residents
aged 60-84 years found a significant reduction in prescribed
antibiotics if they were over the age of 70 years and
taking 60,000 IU of vitamin D3 monthly compared with the
placebo groups. The effect was not significant for those
< 70 years of age. This study suggests that taking
an average of 2000 IU/day vitamin D3 reduces the risk
of infections, most likely respiratory infections, in
older adults.
OBSERVATIONAL STUDIES
OF VITAMIN D
Observational studies provide some of the strongest evidence
to date for beneficial health outcomes related to vitamin
D. Observational studies measure vitamin D status and
health outcomes for every participant. Blood samples are
taken at the time of enrollment and people are followed
for several years. Vitamin D is said to be effective if
positive health outcomes result.
VITAMIN D AND RISK
OF CAUSE SPECIFIC DEATH: SYSTEMATIC REVIEW AND META-ANALYSIS
OF OBSERVATIONAL COHORT AND RANDOMISED INTERVENTION STUDIES
[CHOWDHURY, 2014]
This paper was a review of observational and RCT studies
that showed a correlation between vitamin D and specific
mortality outcomes. One conclusion was that supplementation
with vitamin D3 significantly reduces overall mortality
among older adults. They used data from 73 cohort studies
(849,412 participants) and 22 RCTs (30,716 participants).
In the RCTs, all cause mortality rate was reduced by 11%
for vitamin D3 supplementation but increased by 4% for
vitamin D2 supplementation. In addition, their meta-analysis
of cancer-specific incidence and mortality rates comparing
those who started in the lowest third of vitamin D blood
concentrations against those in the highest third suggests
that vitamin D may have a much stronger impact on survival
after developing cancer than on reducing the risk of developing
cancer to start with.
META-ANALYSIS OF
ALL-CAUSE MORTALITY ACCORDING TO SERUM 25-HYDROXYVITAMIN
D [GARLAND, 2014]
An analysis of 32 observational studies found that as
25(OH)D concentrations increased from 13 nmol/L (5 ng/ml)
to 90 nmol/L (36 ng/ml) there is a linear reduction in
all-cause mortality. At concentrations greater than 90
nmol/L (36 ng/ml), no further improvement was observed.
This finding is important in that it did not find any
evidence for a U-shaped relationship showing higher risk
for both low and high 25(OH)D concentrations as has been
reported in some studies. Furthermore, the risk for all-cause
mortality rate for those with 25(OH)D concentration <
25 nmol/L (10 ng/mL) was 1.9 compared to that for those
with concentrations > 100 nmol/L (40 ng/mL).
LOW VITAMIN D LEVEL
IS AN INDEPENDENT PREDICTOR OF POOR OUTCOMES IN CLOSTRIDIUM
DIFFICILE-ASSOCIATED DIARRHEA [WANG, 2014]
A study in New York found that 25(OH)D concentration and
age were the only independent predictors of response to
the highly fatal Clostridium difficile-associated diarrhea
(CDAD). Subjects with 25(OH)D concentration < 53 nmol/L
(21 ng/mL) were 4.75 times more likely to fail to resolve
CDAD after 30 days than subjects with 25(OH)D concentrations
> 75 nmol/L (30 ng/mL). This is an important finding
since CDAD rates are increasing due to antibiotic resistant
strains of CD.
AVOIDANCE OF SUN
EXPOSURE IS A RISK FACTOR FOR ALL-CAUSE MORTALITY: RESULTS
FROM THE MISS COHORT [LINDQVIST, 2014]
An observational study in Sweden involving 29,518 women
followed for up to 20 years with 2,545 reported deaths
found that the mortality rate for those who avoided sun
exposure was approximately twice as high as those who
were most exposed to the sun. This difference explained
3% of all deaths and is important since UVB doses in Sweden
are generally low and virtually absent for six months
of the year. Production of vitamin D may explain most
of the differences between sun exposure amounts, although
other beneficial effects of solar UV exist, such as release
of nitric oxide resulting in reduction of blood pressure,
as well as vitamin D-independent effects on the immune
system.
25-HYDROXYVITAMIN
D IN THE RANGE OF 20 TO 100 NG/ML AND INCIDENCE OF KIDNEY
STONES [NGUYEN, 2014]
GrassrootsHealth (510c3) initiated a voluntary reporting
project called D*action. There are over 7,000 in the cohort,
of which 2,012 have reported their data for a median of
19 months. In this cohort, there has been no evidence
of an association of 25(OH)D and kidney stones. What was
a risk factor for kidney stones in this study was high
body mass index. This study counters the Women's Health
Initiative study that reported an elevated risk of kidney
stones for women taking 400 IU/d vitamin D3 and 1500 mg/d
calcium.
PREDIAGNOSTIC CIRCULATING
VITAMIN D LEVELS AND RISK OF HEPATOCELLULAR CARCINOMA
IN EUROPEAN POPULATIONS: A NESTED CASE-CONTROL STUDY [FEDIRKO,
2014]
An observational study involving 520,000 participants
in the European Prospective Investigation into Cancer
and Nutrition (EPIC) cohort, of which 138 developed hepatocellular
carcinoma (HCC) or liver cancer, found that higher levels
of 25(OH)D reduced incidence of HCC. Each 10 nmol/L (4
ng/mL) increase in 25(OH)D concentration was associated
with a 20% average decrease in risk of HCC. The large
number of participants in the study with a very small
number of cases indicates the difficulty of demonstrating
the beneficial effect of vitamin D for the rare cancers.
The authors noted that the result did "not change
after adjustment for biomarkers of preexisting liver damage,
nor chronic infection with hepatitis B or C viruses."
PLASMA VITAMIN
D CONCENTRATION INFLUENCES SURVIVAL OUTCOME AFTER A DIAGNOSIS
OF COLORECTAL CANCER [ZGAGA, 2014]
A study in Ireland and Scotland involving 1,598 patients
with stage I to III colorectal cancer, found that 25(OH)D
concentrations (measured approximately 15 weeks after
diagnosis of colorectal cancer) were associated with survival
rates. Those in the highest third of 25(OH)D concentrations
with a median concentration of 51 nmol/L (20 ng/mL) compared
to the lowest third with a median concentration of 10
nmol/L (4 ng/mL) had a 32% lower risk of cancer-specific
mortality rate and a 30% lower risk of all-cause mortality
rate over a ten-year follow-up period. This study provides
support for the idea that people diagnosed with cancer
should raise their 25(OH)D concentration to above a minimum
of 50 nmol/L (20 ng/mL),
META-ANALYSIS OF VITAMIN D SUFFICIENCY FOR IMPROVING SURVIVAL
OF PATIENTS WITH BREAST CANCER [MOHR, 2014]
Two meta-analyses found significantly increased cancer
survival rates with higher concentration of 25(OH)D at
time of diagnosis. For breast cancer, results from five
studies found that those with 25(OH)D concentration of
75 nmol/L (30 ng/mL) had half the 5-20 year mortality
rate as those with a lower concentration of 30 nmol/L
(12 ng/mL).
Could vitamin D sufficiency improve the survival of colorectal
cancer patients? [Mohr, 2014]
In this meta-analysis for colorectal cancer, results from
four studies found that those with 25(OH)D concentration
of 80 nmol/L (32 ng/mL) had 60% of the 6-20 year mortality
rate as those with 45 nmol/L (18 ng/mL).
REDUCED 25-HYDROXYVITAMIN
D AND RISK OF ALZHEIMER'S DISEASE AND VASCULAR DEMENTIA
[AFZAL, 2014]
Two papers reported that those with low 25(OH)D concentrations
had increased risk of developing vascular dementia and
Alzheimer's disease. This first one is from Denmark. A
study involving 418 people followed for 30 years found
a 25% increased risk of Alzheimer's disease and a 22%
increased risk of vascular dementia for those with baseline
25(OH)D concentration < 25 nmol/L (10 ng/ml) compared
to > 50 nmol/L (20 ng/ml)
VITAMIN D AND THE
RISK OF DEMENTIA AND ALZHEIMER DISEASE [LITTLEJOHNS, 2014]
In this second paper on dementia and Alzheimer disease,
a study in the United States involving 1,658 participants
followed for 5.6 years found a 125% increased risk of
Alzheimer's disease for those with severely deficient
25(OH)D levels (< 25 nmol/L (10 ng/mL)), and a 53%
increased risk for those with deficient levels ( = 25
to < 50 nmol/L) compared to participants with sufficient
concentrations ( = 50 nmol/L (20 ng/mL)).
POST-HOC COMPARISON
OF VITAMIN D STATUS AT THREE TIME POINTS DURING PREGNANCY
DEMONSTRATES LOWER RISK OF PRETERM BIRTH WITH HIGHER VITAMIN
D CLOSER TO DELIVERY [WAGNER, 2014]
There is considerable interest in the role of vitamin
D during pregnancy. In a reanalysis of results from two
maternal vitamin D supplementation trials conducted in
South Carolina, it was found that: "(1) maternal
vitamin D status closest to delivery date was more significantly
associated with preterm birth, suggesting that later intervention
as a rescue treatment may positively impact the risk of
preterm delivery, and (2) a serum concentration of 100
nmol/L (40ng/mL) in the 3rd trimester was associated with
a 47% reduction in preterm births."
VITAMIN D IN FETAL
DEVELOPMENT: FINDINGS FROM A BIRTH COHORT STUDY [HART,
2014]
A study in Australia compared maternal 25(OH)D concentration
at 18 weeks' pregnancy with outcomes of the children years
later. The authors found that "maternal vitamin D
deficiency during pregnancy was associated with impaired
lung development in 6-year-old offspring, neurocognitive
difficulties at age 10, increased risk of eating disorders
in adolescence, and lower peak bone mass at 20 years."
VITAMIN D AND PRE-ECLAMPSIA:
ORIGINAL DATA, SYSTEMATIC REVIEW AND META-ANALYSIS [HYPPONEN,
2014]
A review of vitamin D supplementation and 25(OH)D concentrations
during pregnancy found vitamin D reduces the risk of pre-eclampsia.
For 25(OH)D concentration, the combined risk reduction
was 48% with higher level circulating vitamin D. For vitamin
D RCTs, the combined risk reduction was 34% for vitamin
D supplementation vs. a placebo. This review provides
further support for the importance of vitamin D supplementation
and raising 25(OH)D concentrations during pregnancy.
RANDOMIZATION
An approach recently being applied to evaluating whether
vitamin D can be considered causally linked to health
outcomes is Mendelian randomization analysis. In this
approach, genetic variants known to be affected by vitamin
D are compared to health outcomes. The advantage of this
approach is that the results should be independent of
baseline 25(OH)D concentrations, which vary over time.
The disadvantage is that only a few factors are considered
and the most important ones affecting 25(OH)D concentrations
may not be included.
GENETICALLY LOW
VITAMIN D CONCENTRATIONS AND INCREASED MORTALITY: MENDELIAN
RANDOMIZATION ANALYSIS IN THREE LARGE COHORTS [AZFAL,
2014]
In a study involving 95,766 white participants of Danish
descent, genetic variations of DHCR7 (related to vitamin
D synthesis) and CYP2R1 (hepatic 25-hydroxylation), which
slightly lower plasma 25(OH)D concentrations over the
lifetime of the subjects, were examined. As 25(OH)D increased,
significant reductions were found for all-cause, cancer
and other mortality rates, but not for cardiovascular
mortality. These results are interesting, but the method
is not strong enough to rule out a protective role of
vitamin D in reducing risk of cardiovascular disease.
Some regard this approach as particularly weak, since
the serum 25(OH)D concentration depends much more in the
general population upon solar exposure than upon genes.
GUIDELINES FOR
OPTIMIZING DESIGN AND ANALYSIS OF CLINICAL STUDIES OF
NUTRIENT EFFECTS [HEANEY, 2014]
Most vitamin D RCTs were based on guidelines designed
for pharmaceutical drugs where the only source of the
agent is the medication in the trial, and there is a linear
dose-response relation between the agent and the outcome.
Dr. Heaney asserts that neither assumption is valid for
vitamin D trials.
Instead,
vitamin D trials should:
-
Start
with an understanding of the 25(OH)D concentration-health
outcome relationship. What are we expecting to find?
-
Measure
25(OH)D concentrations of prospective trial participants
and only enroll those with values near the low end of
the relation.
-
Supplement
with enough vitamin D to raise 25(OH)D concentrations
to near the upper end of the relation.
-
Measure
25(OH)D concentrations throughout the trial.
-
Optimize
the status of other nutrients related to vitamin D so
that vitamin D is the only limiting factor in the response.
Unfortunately, many
of the ongoing vitamin D trials have not been designed
with these or similar guidelines in mind. As a result,
it may be some time before vitamin D RCTs will be able
to provide adequate evidence to confirm or refute the
findings of observational studies for non-skeletal diseases.
CONCLUSION
Research on the health benefits of solar UVB exposure
and vitamin D continues at a rapid pace. We appear to
be in the middle of the golden age of vitamin D research,
a period with much progress in understanding the effects
of UVB exposure and vitamin D for a large range of health
outcomes. We are shifting from discovery to evaluation
of previous findings and testing the role of vitamin D
in prevention and treatment of various diseases.
While many of the
findings from ecological and observational studies are
strong, it appears that health systems and policy makers
are awaiting results from large on-going RCTs before they
accept UVB exposure and vitamin D as valid factors for
health. Unfortunately, most of the RCTs currently underway
and due to be completed before the end of the decade,
including large-scale RCTs in several countries, have
not been properly designed, so they may not shed light
on vitamin D's preventive powers. Thus, it may be another
decade before the true health benefits of vitamin D and
sunlight are accepted. Meanwhile, various types of research
will continue and it will be up to individuals and their
health care providers to evaluate the available evidence
and act accordingly.
FOR ADDITIONAL
INFORMATION ON SOLAR UVB AND VITAMIN D:
http://www.grassrootshealth.net/
http://www.healthresearchforum.org.uk/
http://www.ncbi.nlm.nih.gov/pubmed
http://scholar.google.com/
http://www.sunarc.org/
http://www.vitamindcouncil.org/
http://www.vitamindsociety.org/
http://www.vitamindwiki.com/VitaminDWiki
OTHER OMNS PRESS
RELEASES ON VITAMIN D
This press release is the fifth in the series on vitamin
D by the Orthomolecular Medicine News Service. Previous
articles:
Vitamin D Stops Cancer; Cuts Risk In Half. American Cancer
Society Drags its Feet. Oct. 2, 2008. http://orthomolecular.org/resources/omns/v04n11.shtml
Why You Need More Vitamin D. A Lot More. Sept. 16, 2011.
http://orthomolecular.org/resources/omns/v07n07.shtml
Top Vitamin D Papers of 2011, Dosage Recommendations and
Clinical Applications. April 10, 2012; http://orthomolecular.org/resources/omns/v08n12.shtml
Vitamin D is Now the Most Popular Vitamin. Jan. 17, 2013.
http://orthomolecular.org/resources/omns/v09n01.shtml
PEER REVIEW BY:
Barbara J Boucher, MD, FRCP, Centre for Diabetes, Blizard
Institute, Bart's & The London School of Medicine
& Dentistry, Queen Mary University of London, London,
UK.
John J. Cannell, MD, Director, Vitamin D Council, San
Luis Obispo, CA, http://www.vitamindcouncil.org/
Cedric F. Garland, DrPH, Professor, Department of Family
and Preventive Medicine, Division of Epidemiology, University
of California San Diego, La Jolla, CA
William B. Grant, Ph.D., Director, Sunlight, Nutrition
and Health Research Center, San Francisco, CA, http://www.sunarc.org/
Michael F. Holick, M.D., Ph.D., Department of Medicine,
Section of Endocrinology, Nutrition, and Diabetes, and
the Vitamin D, Skin, and Bone Research Laboratory, Boston
University Medical Center, Boston, MA, http://drholick.com/,
Interview at http://www.doctoryourself.com/holick.html
Henry Lahore, Director, http://www.vitaminDwiki.com, Port
Townsend, WA
Pawel Pludowski, M.D., Department of Biochemistry, Radioimmunology
and Experimental Medicine, The Children's Memorial Health
Institute, Warsaw, Poland
REFERENCES:
Afzal S, Bojesen SE, Nordestgaard BG. Reduced 25-hydroxyvitamin
D and risk of Alzheimer's disease and vascular dementia.
Alzheimers Dement. 2014 May;10(3):296-302.
Afzal S, Brondum-Jacobsen P, Bojesen SE, Nordestgaard
BG. Genetically low vitamin D concentrations and increased
mortality: mendelian randomisation analysis in three large
cohorts. BMJ. 2014 Nov 18;349:g6330. http://www.ncbi.nlm.nih.gov/pubmed/25406188
Chowdhury R, Kunutsor S, Vitezova A, Oliver-Williams C,
Chowdhury S, Kiefte-de-Jong JC, Khan H, Baena CP, Prabhakaran
D, Hoshen MB, Feldman BS, Pan A, Johnson L, Crowe F, Hu
FB, Franco OH. Vitamin D and risk of cause specific death:
systematic review and meta-analysis of observational cohort
and randomised intervention studies. BMJ. 2014 Apr 1;348:g1903.
http://www.bmj.com/content/348/bmj.g1903?view=long&pmid=24690623
Fedirko V, Duarte-Salles T, Bamia C, Trichopoulou A, Aleksandrova
K, Trichopoulos D, Trepo E, Tjonneland A, Olsen A, Overvad
K, Boutron-Ruault MC, Clavel-Chapelon F, Kvaskoff M, Kühn
T, Lukanova A, Boeing H, Buijsse B, Klinaki E, Tsimakidi
C, Naccarati A, Tagliabue G, Panico S, Tumino R, Palli
D, Bueno-de-Mesquita HB, Siersema PD, Peters PH, Lund
E, Brustad M, Olsen KS, Weiderpass E, Zamora-Ros R, S nchez
MJ, Ardanaz E, Amiano P, Navarro C, Quir¢s JR, Werner
M, Sund M, Lindkvist B, Malm J, Travis RC, Khaw KT, Stepien
M, Scalbert A, Romieu I, Lagiou P, Riboli E, Jenab M.
Prediagnostic circulating vitamin D levels and risk of
hepatocellular carcinoma in European populations: a nested
case-control study. Hepatology. 2014 Oct;60(4):1222-30.
http://www.ncbi.nlm.nih.gov/pubmed/24644045
Garland CF, Kim JJ, Mohr SB, Gorham ED, Grant WB, Giovannucci
EL, Baggerly L, Hofflich H, Ramsdell J, Zeng K, Heaney
RP.Meta-analysis of all-cause mortality according to serum
25-hydroxyvitamin D. Am J Pub Health. 2014 Aug;104(8):e43-50.
http://www.ncbi.nlm.nih.gov/pubmed/24922127
Hart PH, Lucas RM, Walsh JP, Zosky GR, Whitehouse AJ,
Zhu K, Allen KL, Kusel MM, Anderson D, Mountain JA. Vitamin
D in fetal development: Findings from a birth cohort study.
Pediatrics. 2015 Jan;135(1):e167-73. http://www.ncbi.nlm.nih.gov/pubmed/25511121
Heaney RP. Guidelines for optimizing design and analysis
of clinical studies of nutrient effects. Nutr Rev. 2014
Jan;72(1):48-54. http://www.ncbi.nlm.nih.gov/pubmed/24330136
Hyppönen E, Cavadino A, Williams D, Fraser A, Vereczkey
A, Fraser WD, B nhidy F, Lawlor D, Czeizel AE. Vitamin
D and pre-eclampsia: original data, systematic review
and meta-analysis. Ann NutrMetab. 2013;63(4):331-40. (published
in 2014) http://www.ncbi.nlm.nih.gov/pubmed/24603503
Lindqvist PG, Epstein E, Landin-Olsson M, Ingvar C, Nielsen
K, Stenbeck M, Olsson H. Avoidance of sun exposure is
a risk factor for all-cause mortality: results from the
MISS cohort. J Intern Med. 2014 Jul;276(1):77-86. http://www.ncbi.nlm.nih.gov/pubmed/24697969
Littlejohns TJ, Henley WE, Lang IA, Annweiler C, Beauchet
O, Chaves PH, Fried L, Kestenbaum BR, Kuller LH, Lang
KM, Lopez OL, Kos K, Soni M, Llewellyn DJ. Vitamin D and
the risk of dementia and Alzheimer disease.Neurology.
2014 Sep 2;83(10):920-8.
Martineau AR, James WY, Hooper RL, Barnes NC, Jolliffe
DA, Greiller CL, Islam K, McLaughlin D, Bhowmik A, Timms
PM, Rajakulasingam RK, Rowe M, Venton TR, Choudhury AB,
Simcock DE, Wilks M, Degun A, Sadique Z, Monteiro WR,
Corrigan CJ, Hawrylowicz CM, Griffiths CJ. Vitamin D3
supplementation in patients with chronic obstructive pulmonary
disease (ViDiCO): a multicentre, double-blind, randomised
controlled trial. Lancet Respir Med. 2014 Dec 1. pii:
S2213-2600(14)70255-3. doi: 10.1016/S2213-2600(14)70255-3.
[Epub ahead of print] http://www.ncbi.nlm.nih.gov/pubmed/25476069
Mohr SB, Gorham ED, Kim J, Hofflich H, Cuomo RE, Garland
CF. Could vitamin D sufficiency improve the survival of
colorectal cancer patients? J Steroid Biochem Mol Biol.
2014 Dec 19. pii: S0960-0760(14)00316-1. doi: 10.1016/j.jsbmb.2014.12.010.
[Epub ahead of print] http://www.ncbi.nlm.nih.gov/pubmed/25533386
Mohr SB, Gorham ED, Kim J, Hofflich H, Garland CF. Meta-analysis
of vitamin D sufficiency for improving survival of patients
with breast cancer. Anticancer Res. 2014 Mar;34(3):1163-6.
http://www.ncbi.nlm.nih.gov/pubmed/24596354
Nguyen S, Baggerly L, French C, Heaney RP, Gorham ED,
Garland CF. 25-Hydroxyvitamin D in the range of 20 to
100 ng/mL and incidence of kidney stones. Am J Public
Health. 2014 Sep;104(9):1783-7. http://www.ncbi.nlm.nih.gov/pubmed/24134366
Spedding S. Vitamin D and depression: a systematic review
and meta-analysis comparing studies with and without biological
flaws. Nutrients. 2014 Apr 11;6(4):1501-18. http://www.ncbi.nlm.nih.gov/pubmed/24732019
Tran B, Armstrong BK, Ebeling PR, English DR, Kimlin MG,
van der Pols JC, Venn A, Gebski V, Whiteman DC, Webb PM,
Neale RE. Effect of vitamin D supplementation on antibiotic
use: a randomized controlled trial. Am J Clin Nutr. 2014
Jan;99(1):156-61. http://www.ncbi.nlm.nih.gov/pubmed/24108783
Wagner CL, Baggerly C, McDonnell SL, Baggerly L, Hamilton
SA, Winkler J, Warner G, Rodriguez C, Shary JR, Smith
PG, Hollis BW. Post-hoc comparison of vitamin D status
at three time points during pregnancy demonstrates lower
risk of preterm birth with higher vitamin D closer to
delivery. J Steroid Biochem Mol Biol. 2014 Nov 13. pii:
S0960-0760(14)00268-4. doi: 10.1016/j.jsbmb.2014.11.013.
[Epub ahead of print] http://www.ncbi.nlm.nih.gov/pubmed/25448734
Wang WJ, Gray S, Sison C, Arramraju S, John BK, Hussain
SA, Kim SH, Mehta P, Rubin M. Low vitamin D level is an
independent predictor of poor outcomes in Clostridium
difficile-associated diarrhea. Therap Adv Gastroenterol.
2014 Jan;7(1):14-9. http://www.ncbi.nlm.nih.gov/pubmed/24381644
Wong MS, Leisegang MS, Kruse C, Vogel J, Schürmann
C, Dehne N, Weigert A, Herrmann E, Brüne B, Shah
AM, Steinhilber D, Offermanns S, Carmeliet G, Badenhoop
K, Schröder K, Brandes RP. Vitamin D promotes vascular
regeneration. Circulation. 2014 Sep 16;130(12):976-86.
http://www.ncbi.nlm.nih.gov/pubmed/25015343
Zgaga L, Theodoratou E, Farrington SM, Din FV, Ooi LY,
Glodzik D, Johnston S, Tenesa A, Campbell H, Dunlop MG.
Plasma vitamin D concentration influences survival outcome
after a diagnosis of colorectal cancer. J Clin Oncol.
2014 Aug 10;32(23):2430-9. http://www.ncbi.nlm.nih.gov/pubmed/25002714
NUTRITIONAL MEDICINE
IS ORTHOMOLECULAR MEDICINE
Orthomolecular medicine uses safe, effective nutritional
therapy to fight illness. For more information: http://www.orthomolecular.org
FIND A DOCTOR
To locate an orthomolecular physician near you: http://orthomolecular.org/resources/omns/v06n09.shtml
The peer-reviewed Orthomolecular Medicine News Service
is a non-profit and non-commercial informational resource.
EDITORIAL REVIEW
BOARD:
Ian Brighthope, M.D. (Australia)
Ralph K. Campbell, M.D. (USA)
Carolyn Dean, M.D., N.D. (USA)
Damien Downing, M.D. (United Kingdom)
Michael Ellis, M.D. (Australia)
Martin P. Gallagher, M.D., D.C. (USA)
Michael Gonzalez, D.Sc., Ph.D. (Puerto Rico)
William B. Grant, Ph.D. (USA)
Michael Janson, M.D. (USA)
Robert E. Jenkins, D.C. (USA)
Bo H. Jonsson, M.D., Ph.D. (Sweden)
Peter H. Lauda, M.D. (Austria)
Thomas Levy, M.D., J.D. (USA)
Stuart Lindsey, Pharm.D. (USA)
Jorge R. Miranda-Massari, Pharm.D. (Puerto Rico)
Karin Munsterhjelm-Ahumada, M.D. (Finland)
Erik Paterson, M.D. (Canada)
W. Todd Penberthy, Ph.D. (USA)
Gert E. Schuitemaker, Ph.D. (Netherlands)
Robert G. Smith, Ph.D. (USA)
Jagan Nathan Vamanan, M.D. (India)
Atsuo Yanagisawa, M.D., Ph.D. (Japan)
Andrew W. Saul, Ph.D.
(USA), Editor and contact person. Email: omns@orthomolecular.org
This is a comments-only address; OMNS is unable to respond
to individual reader emails. However, readers are encouraged
to write in with their viewpoints. Reader comments become
the property of OMNS and may or may not be used for publication.
To Subscribe at no
charge: http://www.orthomolecular.org/subscribe.html
|
|
|
|
|